E Fund Management Co. Ltd. Takes Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

E Fund Management Co. Ltd. acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 4th quarter, HoldingsChannel reports. The fund acquired 10,785 shares of the biopharmaceutical company’s stock, valued at approximately $273,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Jennison Associates LLC boosted its stake in shares of Celldex Therapeutics by 32.0% in the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after purchasing an additional 321,325 shares during the period. Values First Advisors Inc. boosted its stake in shares of Celldex Therapeutics by 20.0% in the fourth quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company’s stock valued at $733,000 after purchasing an additional 4,837 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Celldex Therapeutics by 293.2% in the third quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company’s stock valued at $958,000 after purchasing an additional 21,013 shares during the period. Bellevue Group AG boosted its stake in shares of Celldex Therapeutics by 3.4% in the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock valued at $104,404,000 after purchasing an additional 100,000 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Celldex Therapeutics in the third quarter valued at approximately $871,000.

Celldex Therapeutics Trading Down 3.1 %

CLDX stock opened at $20.67 on Friday. Celldex Therapeutics, Inc. has a twelve month low of $18.61 and a twelve month high of $49.65. The company’s 50 day moving average is $23.38 and its two-hundred day moving average is $28.44. The stock has a market cap of $1.37 billion, a P/E ratio of -8.04 and a beta of 1.76.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $1.25 million. On average, equities research analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CLDX. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. UBS Group began coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 target price on the stock. Finally, The Goldman Sachs Group reduced their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $55.38.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.